Pierre Fabre Medicament

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pierre Fabre Medicament sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 5 currently recruiting 2 completed early-phase tilt upper quartile by trial count

Pierre Fabre Medicament: 8 sponsored US clinical trials, 5 recruiting.

Pierre Fabre Medicament sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Allogeneic Hematopoietic Cell Transplant, with 2 trials.

Upper-quartile sponsor footprint

Pierre Fabre Medicament sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

NCT06669117
RECRUITING Phase 1

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

NCT06567015
RECRUITING Phase 1

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

NCT06043817
RECRUITING Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

NCT04554914
RECRUITING Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365
ACTIVE NOT RECRUITING Phase 1

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

NCT04913285
COMPLETED Phase 2

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer

NCT03693170
COMPLETED Phase 1

Brain Imaging Study of F17464

NCT01689038

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 2
Phase 3 1

Therapeutic Areas

Allogeneic Hematopoietic Cell Transplant 2
Solid Organ Transplant Complications 2
Stem Cell Transplant Complications 2
Lymphoproliferative Disorders 2
Non-Small Cell Lung Cancer 2
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD) 1
EGFR/HER2 Exon 20 Insertion Mutation 1
MET Alteration 1
EBV+ Sarcomas 1
EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) 1

What is open in the Pierre Fabre Medicament pipeline

5 recruiting of 8 indexed (63% open); 2 completed (25%).

Phase mix: 1 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Allogeneic Hematopoietic Cell Transplant (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pierre Fabre Medicament: open-pipeline peers nationwide

Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.

Pierre Fabre Medicament sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Pierre Fabre MedicamentAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Canadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care SystemNurix Therapeutics
Pierre Fabre Medicament sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pierre Fabre Medicament sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 63% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Pierre Fabre Medicament page

8 registered trials is a research-attention snapshot, not an endorsement of Pierre Fabre Medicament or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pierre Fabre Medicament pipeline card: 8 registered trials from official public datasets.Report a data error.